Ingram, J. R.; Porter, M.; Chovatiya, R.; Giamarellos-Bourboulis, E. J.; Bechara, F. G.; Fujita, H.; Gulliver, W.; Muller, E.; Bari, M.; Rolleri, R.; Byerly, R.; Kirby, J. S. Bimekizumab Response Maintenance to 48 Weeks in Patients With Moderate to Severe Hidradenitis Suppurativa: Pooled Responder Analysis from the Phase 3, Double-Blind, Placebo-Controlled, Randomized Clinical Trials BE HEARD I and II. J of Skin 2024, 8, s396.